Newer treatments of psoriasis regarding IL‐23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors

The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further research. Two drugs which are IL‐23 inhibitors...

Full description

Saved in:

Bibliographic Details
Published in:	Dermatologic therapy Vol. 30; no. 6; pp. e12555 - n/a
Main Authors:	Wcisło‐Dziadecka, Dominika, Zbiciak‐Nylec, Martyna, Brzezińska‐Wcisło, Ligia, Bebenek, Katarzyna, Kaźmierczak, Agata
Format:	Journal Article
Language:	English
Published:	United States 01.11.2017
Subjects:	Animals biological drugs Cyclic Nucleotide Phosphodiesterases, Type 4 - immunology Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Humans IL‐23 inhibitors immune‐modulating Interleukin-23 Subunit p19 - antagonists & inhibitors Interleukin-23 Subunit p19 - immunology Interleukin-23 Subunit p19 - metabolism JAK inhibitors Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - therapeutic use Janus Kinases - antagonists & inhibitors Janus Kinases - metabolism Molecular Targeted Therapy PDE4 inhibitors Phosphodiesterase 4 Inhibitors - adverse effects Phosphodiesterase 4 Inhibitors - therapeutic use psoriasis Psoriasis - diagnosis Psoriasis - drug therapy Psoriasis - enzymology Psoriasis - immunology Signal Transduction - drug effects Skin - drug effects Skin - enzymology Skin - immunology Skin - pathology therapy treatment Treatment Outcome treatment PDE4 inhibitors psoriasis therapy biological drugs IL-23 inhibitors JAK inhibitors immune-modulating
ISSN:	1396-0296, 1529-8019, 1529-8019
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!